<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05623228</url>
  </required_header>
  <id_info>
    <org_study_id>(2022-2024)</org_study_id>
    <secondary_id>(ATH22-24)</secondary_id>
    <nct_id>NCT05623228</nct_id>
  </id_info>
  <brief_title>The Effectiveness and Efficacy of the Combination of the Integrated Psychological Therapy and Metacognitive Training.</brief_title>
  <acronym>ATHSCHIZ</acronym>
  <official_title>The Effectiveness and Efficacy of the Combination of the Integrated Psychological Therapy and Metacognitive Training in Schizophrenia and Treatment Resistant Schizophrenia. This is a Non-randomized Trial. The Therapy Lasts 60 Sessions.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rakitzi, Stavroula</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rakitzi, Stavroula</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The combination of the Integrated Psychological Therapy and Metacognitive Training in&#xD;
      individuals with schizophrenia and treatment resistant schizophrenia.&#xD;
&#xD;
      Is it effective and efficacious?&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Individuals with schizophrenia and treatment resistant schizophrenia will participate on a&#xD;
      group cognitive behavioral therapy and rehabilitation, in which Integrated Psychological&#xD;
      Therapy and Metacognitive Training are going to be implemented. The therapy will last 60&#xD;
      biweekly sessions. This is a non randomized trial.&#xD;
&#xD;
      Speed of processing, working memory, verbal memory, visual memory, reasoning and problem&#xD;
      solving, social cognition, symptoms, functional outcome and recovery will be evaluated&#xD;
      before, after therapy and in a 6 months follow up.&#xD;
&#xD;
      MCCB, Social Perception Scale, the Greek Test for verbal memory, PANSS, WHO DAS 2. 0 (Greek),&#xD;
      PSYRAT and the Recovery Assessment Scale will be used ih this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2022</start_date>
  <completion_date type="Anticipated">December 20, 2024</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Pharmacotherapy in combination with the Integrated Psychological Therapy and Metacognitive Training will be implemented</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cognitive functions: Matrics Consensus Cognitive Battery (MCCB), SPS, Greek Verbal Test</measure>
    <time_frame>45 minutes</time_frame>
    <description>Speed of processing Trail making Test Part A: BACS Symbol coding: Working memory: Letter number span, Greek Verbal memory:&#xD;
Visual learning: Brief Visuospatial Memory, Reasoning and problem solving: NAB Mazes, Social Cognition: Managing emotions (MSCEIT) (MCCB), Social Cognition: Social Perception Scale BACS Symbol coding: the number of the correct symbol coding in 90 seconds. (0-110). The increased score is associated with improvement Working memory: Letter number span: 0-24, the increased score is associated with improvement Rakitzi, S., 2007. The Letter Number Span in Greek. Translation. Unpublished. The LNS was translated in Greek fr</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Symptoms</measure>
    <time_frame>40 minutes</time_frame>
    <description>(PANSS): Lykouras, L., Botsis, A., &amp; Ulis, P. (2005). PANSS. The Greek manual. Athens: Scientific publications. Positive symptoms 8-49, the decreased score is associated with improvement Negative symptoms: 8-49, the decreased score is associated with improvement General Psychopathology: 17-112, the decreased score is associated with improvement&#xD;
(PSYRAT): Haddock, G. , McCarron, J., Tarrier, N. and Faragher, E.B. (1999) Scales to measure dimensions of hallucinations and delusions: the psychotic symptom rating scales (PSYRATS). Psychological Medicine, 29, 879-889&#xD;
Dr. Stavroula Rakitzi has the permission to use this scale Each category has a score 1-4, the decreased score is associated with improvement. To generate a total score for the rating scale overall, calculate the total of all auditory hallucination items. To generate a total score for the rating scale overall, calculate the total of all delusions items.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Functional outcome</measure>
    <time_frame>20 minutes</time_frame>
    <description>WHO DAS 2.0: Koumpouros, I., Sakellari, E., Papageorgiou, E., &amp; Lagiou, A. (2017). WHODAS 2. 0. Greek Manual Koumpouros, I., Papageorgiou, E., Sakellari, E. et al. Adaptation and psychometric properties evaluation of the Greek version of WHODAS 2.0. pilot application in Greek elderly population. Health Services and Outcomes Research Methodology, 2018, 18(1): 63-74. https://doi.org/10.1007/s10742-017-0176-x Calculation 0-100 The decreased score is associated with better functional outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recovery</measure>
    <time_frame>10 minutes</time_frame>
    <description>Recovery Assessment Scale: Hancock, N., Scanlan, J.N., Bundy, A.C., &amp; Honey, A. (2016). Recovery Assessment Scale - Domains &amp; Stages (RAS-DS) Manual- Version 2. Sydney; University of Sydney. The scale is translated in Greek from Dr. Stavroula Rakitzi in cooperation with Prof. Hancock. The increased score is associated with improvement Total score 0-152</description>
  </primary_outcome>
  <other_outcome>
    <measure>Intelligent Quotient</measure>
    <time_frame>90 minutes</time_frame>
    <description>WAIS: Aster Neubauer, Horn. 2006. Wechsler Intelligenz test fuer Erwachsense. Harcourt Test services</description>
  </other_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Therapy Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Therapy Group A Intervention: Pharmacotherapy in combination with the Integrated Psychological Therapy and Metacognitive Training will be implemented.&#xD;
5 individuals with schizophrenia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Therapy Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Therapy Group B Intervention: Pharmacotherapy in combination with the Integrated Psychological Therapy and Metacognitive Training will be implemented.&#xD;
2 individuals with schizophrenia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Therapy Group C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Therapy Group C Intervention: Pharmacotherapy in combination with the Integrated Psychological Therapy and Metacognitive Training will be implemented.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Therapy Group D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Therapy Group D Intervention: Pharmacotherapy in combination with the Integrated Psychological Therapy and Metacognitive Training will be implemented.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Therapy Group E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Therapy Group E Intervention: Pharmacotherapy in combination with the Integrated Psychological Therapy and Metacognitive Training will be implemented.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Therapy Group F</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Therapy Group F Intervention: Pharmacotherapy in combination with the Integrated Psychological Therapy and Metacognitive Training will be implemented.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Therapy Group G</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Therapy Group G Intervention: Pharmacotherapy in combination with the Integrated Psychological Therapy and Metacognitive Training will be implemented.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Therapy Group H</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Therapy Group H Intervention: Pharmacotherapy in combination with the Integrated Psychological Therapy and Metacognitive Training will be implemented.</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>The combination of the Integrated Psychological Therapy and Metacognitive Training in individuals with schizophrenia and treatment resistant schizophrenia</intervention_name>
    <description>The combination of pharmacotherapy and psychotherapy in individuals with schizophrenia and treatment resistant schizophrenia.</description>
    <arm_group_label>Therapy Group A</arm_group_label>
    <arm_group_label>Therapy Group B</arm_group_label>
    <arm_group_label>Therapy Group C</arm_group_label>
    <arm_group_label>Therapy Group D</arm_group_label>
    <arm_group_label>Therapy Group E</arm_group_label>
    <arm_group_label>Therapy Group F</arm_group_label>
    <arm_group_label>Therapy Group G</arm_group_label>
    <arm_group_label>Therapy Group H</arm_group_label>
    <other_name>Pharmacotherapy, rehabilitation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of schizophrenia&#xD;
&#xD;
          -  No relapse and hospitalization&#xD;
&#xD;
          -  Ambulant psychiatric treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other psychotic disorders&#xD;
&#xD;
          -  Relapse and hospitalization&#xD;
&#xD;
          -  Substance abuse&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stavroula Rakitzi, Dr.</last_name>
    <role>Study Director</role>
    <affiliation>Private Practice</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stavroula Rakitzi, Dr</last_name>
    <phone>+302111180571</phone>
    <email>srakitzi@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Polyxeni Georgila, M. D.</last_name>
    <phone>+306932905259</phone>
    <email>polyxenigeorgila@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Stavroula Rakitzi</name>
      <address>
        <city>Athens</city>
        <zip>15771</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stavroula Rakitzi, Dr.</last_name>
      <phone>+2111180571</phone>
      <email>srakitzi@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Polyxeni Georgila, M. D.</last_name>
      <phone>+6932905259</phone>
      <email>polyxenigeorgila@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <link>
    <url>https://www.linkedin.com/</url>
    <description>linkedin Stavroula Rakitzi</description>
  </link>
  <link>
    <url>http://orcid.org</url>
    <description>orcid: 0000-0002-5231-6619</description>
  </link>
  <reference>
    <citation>Rakitzi S, Georgila P. Integrated Psychological Therapy and Treatment-Resistant Schizophrenia: Initial Findings. Psychiatry. 2019 Winter;82(4):354-367. doi: 10.1080/00332747.2019.1616658. Epub 2019 Aug 6.</citation>
    <PMID>31385737</PMID>
  </reference>
  <results_reference>
    <citation>Penney D, Sauve G, Mendelson D, Thibaudeau E, Moritz S, Lepage M. Immediate and Sustained Outcomes and Moderators Associated With Metacognitive Training for Psychosis: A Systematic Review and Meta-analysis. JAMA Psychiatry. 2022 May 1;79(5):417-429. doi: 10.1001/jamapsychiatry.2022.0277.</citation>
    <PMID>35320347</PMID>
  </results_reference>
  <results_reference>
    <citation>Rakitzi S, Georgila P, Efthimiou K, Mueller DR. Efficacy and feasibility of the Integrated Psychological Therapy for outpatients with schizophrenia in Greece: Final results of a RCT. Psychiatry Res. 2016 Aug 30;242:137-143. doi: 10.1016/j.psychres.2016.05.039. Epub 2016 May 30.</citation>
    <PMID>27280523</PMID>
  </results_reference>
  <results_reference>
    <citation>Rakitzi, S., Georgila, P., Becker-Woitag, A.P. (2021). The recovery process for individuals with schizophrenia in the context of evidence based psychotherapy and rehabilitation. A systematic review. European Psychologist, 26(2), 96-111 doi/pdf/10.1027/1016-9040/a000400.</citation>
  </results_reference>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>November 4, 2022</study_first_submitted>
  <study_first_submitted_qc>November 14, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 21, 2022</study_first_posted>
  <last_update_submitted>March 10, 2023</last_update_submitted>
  <last_update_submitted_qc>March 10, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">March 14, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Schizophrenia, treatment resistant schizophrenia, recovery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 14, 2022</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/28/NCT05623228/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 14, 2022</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/28/NCT05623228/SAP_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 14, 2022</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/28/NCT05623228/ICF_002.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

